Price History

Hover for the daily close. The dotted line marks the period open.

Compare NGNE with… →

NGNE Key Statistics

As of Sep 4, 2026

Trading

Open: $37.25
Previous Close: $37.61
Day's Range: 36.56–39.38
52-Week Range: 15.93–43.66
Volume: 205.40K
Beta: 1.96

Valuation

Market Cap: $772.44M
P/E Ratio: unprofitable
EPS (ttm): −5.16

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$90.35M
Profit margin: 0.00%
Shares Outstanding: 20.01M
1-Year Return: +96.84%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 242.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NGNE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+470.37%−89.44%+87.38%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+87.38%
2025	−9.89%
2024	+17.96%
2023	+90.37%
2022	−89.44%
2021	−65.82%
2020	+14.45%
2019	+470.37%
2018	−81.63%
2017	−28.77%
2016 (partial year)	+80.63%

As of September 4, 2026.

NGNE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$90.35M	—
2024	$925.00K	−$75.14M	−8123.7%
2023	$0.00	−$36.32M	—
2022	$0.00	−$55.19M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$103.33M	−$90.35M	—
2024	$925.00K	—	−$82.61M	−$75.14M	−8123.7%
2023	$0.00	—	−$55.58M	−$36.32M	—
2022	$0.00	—	−$56.52M	−$55.19M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NGNE Valuation vs Biotechnology Median

Median of 656 stocks

Metric	NGNE	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Neurogene Inc. (NGNE) is capitalised at $772.44M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 131 employees.

The most recent close on file for NGNE is $38.60, dated September 4, 2026. That is +$0.99 (+2.63%) against the previous close. The 52-week range on file runs from $15.93 to $43.66. The latest close sits 142.31% above that 52-week low.

Financial Health

In fiscal 2025, Neurogene Inc. reported revenue of $0.00. Against the prior fiscal year total of $925.00K, that is a change of −100.00%. The same year closed with a net loss of $90.35M. Profit margin runs at 0%. Trailing earnings per share are −5.16.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 1.96. Daily returns over the trailing 10 years annualize to a volatility of 87.69%. The trailing one-year price return is +96.84%. Measured over 10 years, that is −16.80% a year compounded.

Growth & Income

The record shows no dividend for NGNE.

Across the complete calendar years on file, 2019 returned +470.37% and 2022 returned −89.44%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is +87.38%.

Peer Comparison

Neurogene Inc. (NGNE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Neurogene Inc.	NGNE	$772.44M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Neurogene Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Neurogene Inc.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Visit website →

Neurogene Inc. (NGNE) Stock Analysis